SCHEMBL607745

SCHEMBL607745

FC(CN1CCNCC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAX Q07812 2/20 0.72
MAPT P10636 3/20 0.70
TP53 P04637 1/20 0.70
CYP3A4 P08684 1/20 0.70
ALOX15 P16050 1/20 0.70
MAPK1 P28482 1/20 0.70
RAD52 P43351 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TSPO P30536 3/20 0.44
DNM1 Q05193 4/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
OPRM1 P35372 1/20 0.42
P2RX3 P56373 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
IDO1 P14902 1/20 0.38
DNMT1 P26358 1/20 0.38
PER2 O15055 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29992291 1.00 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL5024339 1.00 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL5024320 1.00 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL29398838 1.00 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
Hydrochloric Acid SCHEMBL31038642 0.99 MAPT (0.73) BAXMAPTTP53CYP3A4ALOX15
Hydrochloric Acid SCHEMBL29462932 0.99 MAPT (0.73) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL19419604 0.93 BAX (0.63) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL5024368 0.84 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL607771 0.84 BAX (0.72) BAXMAPTTP53CYP3A4ALOX15
SCHEMBL609012 0.84 BAX (1.00) BAXMAPTTP53CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US claimed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US claimed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP claimed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO claimed
EP-1094063-A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators Applied Research Systems ARS Holding N.V. (AN) 2001-04-25 EP claimed
CN-116096363-A Coronavirus proliferation method 花王株式会社 2023-05-09 CN disclosed
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES UNITY BIOTECHNOLOGY, INC. 2017-10-05 US disclosed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed
EP-1237887-A1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS Applied Research Systems ARS Holding N.V. (AN) 2002-09-11 EP disclosed
WO-2001029028-A1 9- (PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-26 WO disclosed
EP-1094063-A1 9-(Piperazinylalkyl)carbazoles as Bax-modulators Applied Research Systems ARS Holding N.V. (AN) 2001-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281649-A1 COMPOUNDS AND THERAPEUTIC USES TP53, NQO1, SHMT2 BAX 705/4885MAPT 1762/4885TP53 1/4885
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD BAX 2/4885MAPT 1085/4885TP53 1113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.